Skip to main content

MRVI

Stock
Health Care
Biotechnology

Performance overview

MRVI Price
Price Chart

Forward-looking statistics

Beta
0.97
Risk
91.29%

Detailed forecast

[disclaimer]

Individual forecast components (weighted-sum)

Company Profile

Maravai LifeSciences Holdings Inc is a life sciences company. It provides products to enable the development of drug therapies, diagnostics, and novel vaccines and supports research on human diseases. Its reportable segments are Nucleic acid production and biologics safety testing. It generates a majority of its revenue from Nucleic Acid Production and focuses on the manufacturing and sale of nucleic acid products to support the needs of customers' research, and therapeutic and vaccine programs. In addition, the segment also provides research products for labeling and detecting proteins in cells and tissue samples.

Company info

SectorHealth Care
IndustryBiotechnology
Employees347
Market cap$1.1B

Fundamentals

Enterprise value$672.6M
Revenue$241.9M
Revenue per employee—
Profit margin-67.28%
Debt to equity71.85

Security info

ExchangeNASDAQ
Type of shareCommon Stock
Earnings per share (EPS)-$1.17
Dividend per share—
Revenue per share$1.72
Avg trading volume (30 day)$5M
Avg trading volume (10 day)$6M
Put-call ratio—

Macro factor sensitivity

Growth-4.2
Credit+7.1
Liquidity+0.5
Inflation-6.3
Commodities-1.0
Interest Rates-1.6

Valuation

Dividend yield0.00%
PEG Ratio1.70
Price to sales4.03
P/E Ratio289.00
Enterprise Value to Revenue2.78
Price to book1.28

Upcoming events

Next earnings dayMay 13, 2025
Next dividend day—
Ex. dividend day—

News

These Analysts Slash Their Forecasts On Maravai LifeSciences Following Q1 Results

Maravai LifeSciences Holdings, Inc. MRVI reported mixed results for the first quarter on Monday.

Benzinga (May 13, 2025)
Maravai LifeSciences Holdings, Inc. (MRVI) Reports Q1 Loss, Tops Revenue Estimates

Maravai LifeSciences Holdings, Inc. (MRVI) came out with a quarterly loss of $0.08 per share versus the Zacks Consensus Estimate of a loss of $0.07. This compares to loss of $0.02 per share a year ago.

Zacks Investment Research (May 12, 2025)

Unlock Personalized Financial Tools

All our core financial tools are completely free. Create an account to save your research, get personalized recommendations, and enjoy unlimited access.

Save research to draft portfolios
Get personalized recommendations
Access unlimited tool usage
Sign up for free